title: Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines.
abstract: Myeloid regulatory cells (Mregs) are, together with regulatory T cells (Tregs), a dominant effector population responsible for restriction of the duration and strength of antitumor immune response. Photodynamic therapy (PDT) and cancer vaccines generated by PDT are modalities whose effectiveness in tumor destruction is closely dependent on the associated antitumor immune response. The present study investigated whether the immunodepletion of granulocytic Mregs in host mice by anti-GR1 antibody would improve the response of tumors to PDT or PDT vaccines in these animals. Anti-GR1 administration immediately after Temoporfin-PDT of mouse SCCVII tumors abrogated curative effect of PDT. The opposite effect, increasing PDT-mediated tumor cure-rates was attained by delaying anti-GR1 treatment to 1 h post PDT. With PDT vaccines, multiple anti-GR1 administrations (days 0, 4, and 8 post vaccination) improved the therapy response with SCCVII tumors. The results with PDT suggest that neutrophils (boosting antitumor effect of this therapy) that are engaged immediately after photodynamic light treatment are within one hour replaced with a different myeloid population, presumably Mregs that hampers the therapy-mediated antitumor effect. Anti-GR1 antibody, when used with optimal timing, can improve the efficacy of both PDT of tumors in situ and PDT-generated cancer vaccines.
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada. mkorbelik@bccrc.ca.
authors.forename: Mladen
authors.initials: M
authors.lastname: Korbelik
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada. jbanath@bccrc.ca.
authors.forename: Judith
authors.initials: J
authors.lastname: Banáth
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada. wzhang@bccrc.ca.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
keywords: Mregs; anti-GR1 antibody; cancer vaccines; photodynamic therapy